Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Université de Montpellier, 30207 Bagnols-sur-Cèze, France.
Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SPI, 30200 Bagnols-sur-Cèze, France.
Genes (Basel). 2021 Jun 9;12(6):892. doi: 10.3390/genes12060892.
Cystic fibrosis (CF) is a hereditary disease caused by mutations in the CF transmembrane conductance regulator () gene, triggering dysfunction of the anion channel in several organs including the lung and gut. The main cause of morbidity and mortality is chronic infection. The microbiota is now included among the additional factors that could contribute to the exacerbation of patient symptoms, to treatment outcome, and more generally to the phenotypic variability observed in CF patients. In recent years, various omics tools have started to shed new light on microbial communities associated with CF and host-microbiota interactions. In this context, proteomics targets the key effectors of the responses from organisms, and thus their phenotypes. Recent advances are promising in terms of gaining insights into the CF microbiota and its relation with the host. This review provides an overview of the contributions made by proteomics and metaproteomics to our knowledge of the complex host-microbiota partnership in CF. Considering the strengths and weaknesses of proteomics-based approaches in profiling the microbiota in the context of other diseases, we illustrate their potential and discuss possible strategies to overcome their limitations in monitoring both the respiratory and intestinal microbiota in sample from patients with CF.
囊性纤维化 (CF) 是一种遗传性疾病，由 CF 跨膜电导调节因子 () 基因突变引起，导致肺和肠道等多个器官中的阴离子通道功能障碍。发病率和死亡率的主要原因是慢性感染。微生物组现在被认为是导致患者症状恶化、治疗结果以及 CF 患者表型变异性的额外因素之一。近年来，各种组学工具开始揭示与 CF 相关的微生物群落及其与宿主微生物群相互作用的新信息。在这种情况下，蛋白质组学针对生物体反应的关键效应物，从而针对其表型。最近的进展有望深入了解 CF 微生物群及其与宿主的关系。这篇综述概述了蛋白质组学和代谢蛋白质组学在 CF 中复杂的宿主-微生物群伙伴关系方面的贡献。考虑到基于蛋白质组学的方法在 profiling 微生物群方面的优缺点在其他疾病中的应用，我们说明了它们的潜力，并讨论了可能的策略来克服在监测 CF 患者样本中的呼吸道和肠道微生物群时克服它们的局限性。
